These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
974 related articles for article (PubMed ID: 31185212)
1. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212 [TBL] [Abstract][Full Text] [Related]
2. NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury. Wu X; Lahiri A; Haines GK; Flavell RA; Abraham C J Immunol; 2014 Apr; 192(7):3409-18. PubMed ID: 24591373 [TBL] [Abstract][Full Text] [Related]
3. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
4. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098 [TBL] [Abstract][Full Text] [Related]
5. LINC00152 mediates CD8 Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190 [TBL] [Abstract][Full Text] [Related]
6. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. Ohtani H; Jin Z; Takegawa S; Nakayama T; Yoshie O J Pathol; 2009 Jan; 217(1):21-31. PubMed ID: 18980207 [TBL] [Abstract][Full Text] [Related]
8. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Ikeda A; Aoki N; Kido M; Iwamoto S; Nishiura H; Maruoka R; Chiba T; Watanabe N Hepatology; 2014 Jul; 60(1):224-36. PubMed ID: 24700550 [TBL] [Abstract][Full Text] [Related]
9. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8 Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055 [TBL] [Abstract][Full Text] [Related]
11. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856 [TBL] [Abstract][Full Text] [Related]
12. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Karin N Front Immunol; 2020; 11():976. PubMed ID: 32547545 [TBL] [Abstract][Full Text] [Related]
13. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952 [TBL] [Abstract][Full Text] [Related]
14. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589 [TBL] [Abstract][Full Text] [Related]
18. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody. Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350 [TBL] [Abstract][Full Text] [Related]
19. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609 [TBL] [Abstract][Full Text] [Related]
20. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Wong JL; Berk E; Edwards RP; Kalinski P Cancer Res; 2013 Aug; 73(15):4653-62. PubMed ID: 23761327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]